Ensign Peak Advisors
APLT

Ensign Peak Advisors’s Applied Therapeutics APLT Stock Holding History

Ensign Peak Advisors’s Portfolio APLT Stock Details APLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-11,940
Closed -$107K – 2210
2021
Q4 		$107K Buy
+11,940
New +$157K ﹤0.01% 2048

Other funds holding APLT

Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ensign Peak Advisors's APLT Position: Q1 2022 in Review

Ensign Peak Advisors sold out of Applied Therapeutics (APLT) in Q1 2022, closing a stake of 11,940 shares — an estimated $107K sold.

Ensign Peak Advisors first reported a position in APLT in Q4 2021 and held it in 1 quarter. The position peaked at $107K in Q4 2021. 71 funds tracked by Wall St. Rank hold APLT as of Q1 2022.

  • Ensign Peak Advisors reported no remaining Applied Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Ensign Peak Advisors sold 11,940 Applied Therapeutics shares in Q1 2022, an estimated $107K.
  • Ensign Peak Advisors first reported a position in Applied Therapeutics in Q4 2021 and held it in 1 quarter.
  • Ensign Peak Advisors's Applied Therapeutics position peaked at $107K in Q4 2021.
  • 71 funds tracked by Wall St. Rank held Applied Therapeutics as of Q1 2022.

Based on Ensign Peak Advisors's 13F filing for Q1 2022, filed 16 May 2022.